证券代码：688253 证券简称：英诺特 公告编号：2025-025 北京英诺特生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/3 | | | | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 日~2025 月 2024 8 2 8 1 | 年 | 日 | | 预计回购金额 | 5,000万元~10,000万元 | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | □用于转换公司可转债 | | | | | □为维护公司价值及股东权益 | | | | 累计已回购股数 | 211.2740万股 | | | | 累计已回购股数占总股本比例 | 1.5483% | | | | 累计已回购金额 | 7,801.24万元 | | | | 实际回购价格区间 | 28.62元/股~45.37元/股 | | | 一、回购股份的基本情况 2024 ...

Core Viewpoint - The shareholder meeting of Beijing Innotech Biotechnology Co., Ltd. was held on May 22, 2025, with all proposed resolutions passing successfully, indicating strong shareholder support and compliance with legal requirements [1][2][3]. Meeting Details - The meeting took place at the conference room on the 7th floor of Building 2, No. 1 Haiying Road, Fengtai District, Beijing [1]. - A total of 64 ordinary shareholders attended, holding 72,974,432 voting rights, which accounted for 54.3185% of the company's total voting rights [1]. Voting Results - All non-cumulative voting proposals were approved with significant majority support: - Proposal votes: 72,937,802 in favor (99.9498%), 34,230 against (0.0469%), and 2,400 abstentions (0.0033%) [1][2]. - Similar voting patterns were observed across multiple proposals, consistently showing over 99% approval from ordinary shareholders [2][3]. Legal Compliance - The meeting's convening and voting procedures adhered to the requirements set forth by the Company Law of the People's Republic of China and the company's articles of association, ensuring the legitimacy of the proceedings [1][3].

Core Viewpoint - The legal opinion confirms the legitimacy of the 2024 annual general meeting of Beijing Innotech Biotechnology Co., Ltd., ensuring compliance with relevant laws and regulations [1][11]. Group 1: Meeting Procedures - The notice for the 2024 annual general meeting was properly issued, detailing the time, location, agenda, and registration methods for shareholders [3][4]. - The meeting was held at the specified location and was presided over by the chairman, Ye Fengguang [4][5]. Group 2: Attendance and Qualifications - A total of 7 shareholders attended the meeting in person, representing 68,709,082 shares, which is a significant portion of the voting rights [6]. - 57 shareholders participated in the online voting, with their qualifications verified by the Shanghai Stock Exchange [6][11]. Group 3: Voting Procedures and Results - The meeting utilized both on-site and online voting methods, with results being monitored and counted by designated personnel [7][11]. - Various resolutions were passed with overwhelming support, including votes where over 99% of the attending shareholders approved the proposals [7][10].

证券代码：688253 证券简称：英诺特 公告编号：2025-024 北京英诺特生物技术股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 64 | | --- | --- | | 普通股股东人数 | 64 | | 2、出席会议的股东所持有的表决权数量 | 72,974,432 | | 普通股股东所持有表决权数量 | 72,974,432 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 54.3185 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 54.3185 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 （一） 股东大会召开的时间：2025 年 5 月 22 日 （二） 股东大会召开的地点：北京市 ...

北京市中伦律师事务所 关于北京英诺特生物技术股份有限公司 2024 年年度股东大会的 法律意见书 2025 年 5 月 北京市中伦律师事务所 关于北京英诺特生物技术股份有限公司 2024 年年度股东大会的 法律意见书 致：北京英诺特生物技术股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受北京英诺特生物技术股份有 限公司（以下简称"公司"）委托，指派本所律师对公司 2024 年年度股东大会（以 下简称"本次股东大会"）的合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会（以 下简称"中国证监会"）《上市公司股东会规则》（以下简称"《股东会规则》"）等 现行有效的法律、法规、规范性文件以及《北京英诺特生物技术股份有限公司章 程》（以下简称"《公司章程》"）的规定而出具。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件等材料、口头证言均符合真实、准 ...

华泰联合证券有限责任公司 关于北京英诺特生物技术股份有限公司 2024 年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司名称：北京英诺特生物技术股份有限 | | --- | --- | | | 公司 | | 保荐代表人姓名：丁明明 | 联系电话：010-56839300 | | 保荐代表人姓名：郑明欣 | 联系电话：010-56839300 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科创 板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以下简 称"华泰联合"或"保荐机构"）作为北京英诺特生物技术股份有限公司（以下简称 "英诺特"或"公司"）首次公开发行股票的保荐机构，对英诺特进行持续督导，并出 具 2024 年度（以下简称"本报告期"或"报告期"）持续督导跟踪报告： 一、持续督导工作情况 | 序号 | 项目 | 持续督导工作情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度， | 保荐机构已制定并严格执行持续督导 | | 1 | 并针对具体的持续督导工作制定相应的工 | 工作制度，已根据公司的 ...

Group 1 - The core viewpoint of the article highlights that Innotech's stock closed at 31.5 yuan, down 1.25%, with a rolling PE ratio of 21.92 times and a total market capitalization of 4.298 billion yuan [1] - Innotech operates in the bioproducts industry, which has an average PE ratio of 57.79 times and a median of 38.07 times, placing Innotech at the 34th position in the industry ranking [1] - As of the first quarter of 2025, four institutions held shares in Innotech, with a total of 5.2561 million shares valued at 183 million yuan [1] Group 2 - Innotech's main business focuses on the research, production, and sales of POCT rapid diagnostic products, primarily targeting respiratory pathogen detection, while also covering areas such as reproductive health, digestive tract, and hepatitis testing [1] - The latest performance report for the first quarter of 2025 shows that Innotech achieved an operating revenue of 207 million yuan, a year-on-year decrease of 26.51%, and a net profit of 95.2897 million yuan, down 34.77%, with a gross profit margin of 83.12% [1]

北京英诺特生物技术股份有限公司 2024 年年度股东大会会议资料 证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 22 日 1 / 30 北京英诺特生物技术股份有限公司 2024 年年度股东大会会议资料 北京英诺特生物技术股份有限公司 2024 年年度股东大会会议资料目录 | 年年度股东大会会议须知 2024 3 | | --- | | 2024 年年度股东大会会议议程 5 | | 年年度股东大会会议议案 2024 7 | | 议案一：关于公司 2024 年年度报告及其摘要的议案 7 | | 议案二：关于公司 年度财务决算报告的议案 8 2024 | | 议案三：关于公司 2025 年度财务预算报告的议案 9 | | 议案四：关于 年度董事会工作报告的议案 10 2024 | | 议案五：关于 2024 年度监事会工作报告的议案 11 | | 议案六：关于公司 2024 年年度利润分配方案的议案 12 | | 议案七：关于续聘公司 2025 年度审计机构的议案 13 | | 议案八：关于 2025 年度董事薪酬方案的议案 14 ...

一、回购股份的基本情况 证券代码：688253 证券简称：英诺特 公告编号：2025-023 北京英诺特生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/3 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 12 | | 预计回购金额 | 5,000万元~10,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | 累计已回购股数 | □为维护公司价值及股东权益 211.2740万股 | | 累计已回购股数占总股本比例 | 1.5483% | | 累计已回购金额 | 7,801.24万元 | | 实际回购价格区间 | 28.62元/股~45.37元/股 | 特此公告。 北京英诺特生物技术股份有限公司董事会 2025 年 5 月 7 日 2024 年 8 月 2 日，公司召开第二届董事会第五次会议，会议审议通过了《关 于 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company has shown significant growth in its respiratory multi-detection products, with a revenue increase of 29.99% year-on-year, reaching 621 million yuan in 2024. The net profit attributable to the parent company also increased by 41.92% to 247 million yuan [6][8] - The company is expanding its product offerings in Alzheimer's disease (AD) detection through a strategic partnership with Quanterix, leveraging advanced digital immunoassay technology for early diagnosis and screening [7][8] - The company is expected to achieve steady revenue and profit growth in the coming years, with projected revenues of 729 million yuan in 2025, 828 million yuan in 2026, and 921 million yuan in 2027, reflecting year-on-year growth rates of 17.3%, 13.6%, and 11.3% respectively [8] Financial Summary - In 2024, the company achieved a total revenue of 621 million yuan, with a year-on-year growth of 30.0%. The net profit attributable to the parent company was 247 million yuan, with a net profit growth of 41.9% [11] - The projected financials for 2025 to 2027 indicate a consistent growth trajectory, with net profits expected to reach 280 million yuan in 2025, 325 million yuan in 2026, and 390 million yuan in 2027, corresponding to growth rates of 13.5%, 15.9%, and 20.1% respectively [11] - The company's gross margin is projected to remain strong, with estimates of 80.1% in 2024, 83.8% in 2025, and gradually declining to 79.3% by 2027 [11]